Item 1A Risk Factors.
−Removed: There have been no material changes from the risk factors previously disclosed in the Company’s most recent Annual Report on Form 10-K as filed with the SEC on March 25, 2022 and Quarterly Reports on Form 10-Q as filed with the SEC on May 11, 2022 and August 9, 2022.
+Added: There have been no material changes from the risk factors previously disclosed in the Company’s most recent Annual Report on Form 10-K as filed with the SEC on March 24, 2023.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
10 unchanged sentences
● the rate and degree of market acceptance and clinical utility of our current and future product candidates;
−Removed: ● our expectations surrounding the payments we expect to receive pursuant to the AstraZeneca License Agreement;
+Added: ● any expectations surrounding the payments we could potentially receive pursuant to the AstraZeneca License Agreement;
● the ability and willingness of our third-party collaborators to continue research and development activities relating to our product candidates;
8 unchanged sentences
● our expectations about market trends;
−Removed: ● the impact of global economic and political developments on our business, including rising inflation and capital market disruptions, the current conflict in Ukraine, economic sanctions and economic slowdowns or recessions that may result from such developments which could harm our research and development efforts as well as the value of our common stock and our ability to access capital markets;
−Removed: ● our ability to overcome the challenges posed by the COVID-19 pandemic to the conduct of our business;
+Added: ● the impact of global economic and political developments on our business, including rising or sustained high inflation and capital market disruptions, the current conflict in Ukraine, disruptions in the banking industry, economic sanctions and economic slowdowns or recessions that may result from such developments which could harm our research and development efforts as well as the value of our ordinary shares and ability to access capital markets;
● our expectations regarding the period during which we qualify as an emerging growth company under the Jumpstart Our Business Startups Act of 2012, as amended.
8 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.